A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

Biological Psychiatry
Joseph I FriedmanKenneth L Davis

Abstract

Despite the beneficial effects of atypical antipsychotics on cognition, these improvements will not return most schizophrenic patients to normative standards of cognitive functioning. Therefore, other treatments need to be considered. Subtle changes in cholinergic function in schizophrenic patients provide the rationale to test the effectiveness of cholinesterase inhibitors in treating cognitive impairment in schizophrenia. Given this, a 12-week, double-blind, placebo-controlled trial of donepezil (5 mg and 10 mg) as adjunctive treatment to risperidone was conducted in a total of 36 schizophrenic patients. Neither the 5-mg nor 10-mg dose of donepezil produced significant improvements in any cognitive measure compared with placebo. It is possible that nicotinic receptor desensitization produced by chronic tobacco use in these patients rendered their nicotinic receptors refractory to the effects of increased agonist activity produced by donepezil. An alternative treatment is the allosterically potentiating ligands, which enhance the activity of (sensitize) nicotinic receptors in the presence of acetylcholine.

References

Oct 20, 1977·Psychopharmacology·D BlozovskiD Garrigou
Jul 31, 1992·Brain Research·V Luntz-LeybmanR Freedman
Nov 1, 1991·The American Journal of Psychiatry·K L DavisM Davidson
Jan 1, 1991·The Journal of Neuropsychiatry and Clinical Neurosciences·R S el-MallakhJ E Kleinman
Apr 15, 1991·Biological Psychiatry·J GeddesP Pratt
Aug 1, 1986·The American Journal of Psychiatry·J R HughesL A Dahlgren
Jan 1, 1986·Behavioral and Neural Biology·T G Aigner, M Mishkin
Nov 1, 1973·Pharmakopsychiatrie, Neuro-Psychopharmakologie·J ModestinJ Hunger
Aug 1, 1981·The American Journal of Psychiatry·P EdelsteinD L Garver
Feb 1, 1994·Archives of General Psychiatry·A J SaykinR C Gur
May 1, 1994·Schizophrenia Research·V HaroutunianK L Davis
Dec 1, 1993·The American Journal of Psychiatry·L E AdlerR Freedman
Mar 1, 1993·Neurobiology of Aging·M J CallahanR E Davis
Jan 1, 1996·Schizophrenia Bulletin·S LeonardR Freedman
Jan 1, 1995·Journal of Receptor and Signal Transduction Research·A MaelickeE X Albuquerque
Jan 21, 1997·Proceedings of the National Academy of Sciences of the United States of America·R FreedmanW Byerley
Jun 1, 1997·The American Journal of Psychiatry·M F GreenJ Mintz
Jun 5, 1998·Schizophrenia Bulletin·L E AdlerR Freedman
Aug 27, 1998·Schizophrenia Bulletin·P PowchikK L Davis
Dec 5, 1998·British Journal of Clinical Pharmacology·S L Rogers, L T Friedhoff
Apr 20, 2000·European Journal of Pharmacology·E D Levin, A H Rezvani
Aug 11, 2000·The Journal of Clinical Psychiatry·M F WeinerD A Svetlik
Sep 16, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C R BreeseS Leonard
Feb 7, 2001·The American Journal of Psychiatry·P D Harvey, R S Keefe
Mar 15, 2001·The Journal of Clinical Psychiatry·S N CaroffS C Mann
Mar 30, 2001·Schizophrenia Research·R M KirraneL J Siever

❮ Previous
Next ❯

Citations

Sep 28, 2004·Der Nervenarzt·K Cattapan-LudewigF Hasler
Mar 22, 2005·Psychopharmacology·Oliver FreudenreichDonald C Goff
Sep 4, 2008·Psychopharmacology·Cherrie Galletly
Jan 16, 2007·Journal of Autism and Developmental Disorders·J Helen YooDean C Williams
Jun 10, 2009·Neuropsychology Review·Philip D Harvey
May 4, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yuly BersudskyJoel Walters
Jun 16, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·John G CsernanskyHongxin Dong
Apr 28, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Björn SchilströmTorgny H Svensson
Jul 13, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Richard S E KeefeRobert Goldman
Aug 11, 2007·Cognitive Neuropsychiatry·Christian G KohlerRuben C Gur
May 17, 2007·Schizophrenia Bulletin·William S Stone, Larry J Seidman
Jul 10, 2007·Schizophrenia Bulletin·John A Gray, Bryan L Roth
Dec 4, 2003·Clinical Neuropharmacology·Alessandro LenziElisabetta Coli
Aug 3, 2005·Clinical Neuropharmacology·Steven K EricksonGregory A Light
Aug 25, 2007·Annual Review of Clinical Psychology·Michael F Green
Oct 12, 2010·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Yukio Ago
Dec 1, 2006·Neuropsychiatric Disease and Treatment·Christopher R Bowie, Philip D Harvey
Sep 4, 2013·The British Journal of Psychiatry : the Journal of Mental Science·Kee-Hong ChoiMatthew M Kurtz
Jan 1, 2006·Indian Journal of Psychiatry·J K Trivedi
Mar 16, 2007·Current Medical Research and Opinion·Sylvie ChouinardHenri Cohen
Dec 1, 2010·Pharmacology, Biochemistry, and Behavior·Donald C GoffDeanna Barch
Aug 30, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shahin AkhondzadehSams-Ali Rezazadeh
Jun 19, 2008·L'Encéphale·O Kebir, K Tabbane
Jan 1, 2004·Bipolar Disorders·Glenda Macqueen, Trevor Young
Jun 23, 2009·Bipolar Disorders·Joseph F Goldberg, K N Roy Chengappa
Jun 27, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·M PérezZ Lenderová
Apr 6, 2004·The Psychiatric Clinics of North America·Laura A Flashman, Michael F Green
Mar 23, 2005·Biological Psychiatry·Richard S E KeefeMargaret P Poe
Oct 19, 2010·CNS Neuroscience & Therapeutics·Max Jean-Lon ChenJohn H Gruzelier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here